LYL1 is critical for adult hematopoietic stem cell-derived B and T lymphopoiesis Authors: Sung K Chiu, James The, Jesslyn Saw, Jacqueline A Boyle, David J Curtis, Cedric S Tremblay Published: 2026 ABSTRACT AbstractHematopoietic stem cells (HSCs) are defined by their remarkable self-renewal and differentiation capacities, giving rise to progenitors that generate diverse blood and immune cell lineages through the tightly regulated process of hematopoiesis. This process is governed by key transcription factors that control gene expression programs essential for cellular homeostasis, differentiation, and lineage commitment. The transcription factor Lyl1 plays a critical role in regulating HSC function and the lineage specification of hematopoietic progenitors. To investigate its role in adult hematopoiesis, we developed a novel conditional Lyl1 knockout (KO) mouse model. Conditional deletion of Lyl1 in adult mice resulted in reduced HSC and lymphoid progenitor populations, consistent with findings from constitutive Lyl1 KO models. Despite these reductions, mature B- and T-lymphocyte numbers remained unchanged, in contrast to previous reports from embryonically deleted Lyl1 models. Competitive transplantation assays further confirmed that Lyl1 is essential for the generation of adult HSC-derived lymphoid progenitors that support adaptive T- and B-cell production. Our new conditional Lyl1 KO model provides a valuable tool for dissecting Lyl1 function across developmental stages and uncovering the mechanisms that maintain postnatal hematopoietic homeostasis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53398-3.Subject terms: Cell biology, Developmental biology, Immunology, Stem cells Introduction Hematopoiesis is the process by which hematopoietic stem cells (HSCs) continuously generate the full spectrum of blood and immune cells throughout life. This lifelong regenerative capacity depends on the ability of HSCs to both self-renew and differentiate into lineage-restricted progenitors that give rise to all mature hematopoietic cells1–3. The fate of HSCs is tightly regulated by key transcription factors (TFs), which orchestrate gene expression programs necessary for cellular homeostasis, differentiation, and lineage commitment4–7. Unlike more committed hematopoietic populations, HSCs have more complex TF networks that allow fine degrees of cell fate determination8,9. Longitudinal characterization of the dynamic changes in TF complexes associated with different stages of differentiation, as well as regulatory sequences bound by these TFs have identified key cell-fate determinants throughout hematopoiesis10. A heptad of TFs formed by interactions between FLI1, ERG, GATA2, RUNX1, LMO2 with the related basic helix-loop-helix (bHLH) factors TAL1 and LYL1 bind to essential genes for supporting hematopoietic stem and progenitor cell (HSPC) function11–17. These factors form a densely interconnected transcriptional circuit that supports stem and progenitor cell function and ensures proper lineage progression8,17. Disruption of this network, through mutations or dysregulation, is frequently implicated in hematologic malignancies14,18–20. LYL1, a member of the bHLH family and a close paralog of TAL1, was initially identified in T-cell acute lymphoblastic leukemia (T-ALL) due to translocations leading to its aberrant overexpression18,21–23. While TAL1 is indispensable during early embryonic hematopoiesis, its expression is downregulated in adult lymphoid progenitors, where LYL1 becomes more prominent, suggesting context-specific and possibly compensatory roles12,13. In the lymphoid lineage, LYL1 expression is high in lymphoid-primed multipotent progenitors (MPPLy) and declines through T-cell maturation, while remaining sustained in the B-cell lineage13,24,25. Functional studies in Lyl1-deficient mice have demonstrated a crucial, non-redundant role for LYL1 in lymphoid development. Constitutive knockout (KO) of Lyl1 results in severe impairments in early T-cell development, including a loss of early thymic progenitors (ETPs) and CD4−CD8− double-negative 2 (DN2) T-cell progenitors due to increased apoptosis11,26. Similarly, B-lymphocyte development is compromised by a block at the pro-B to pre-B transition, leading to reduced peripheral B-cell numbers13. Transplantation and in vitro colony-forming assays have further revealed that Lyl1-deficient HSPCs are intrinsically unable to give rise to T and B lineages13,26. Despite these insights, much of our current understanding comes from constitutive KO models, where deletion of Lyl1 occurs during embryonic development26–30. This raises the possibility that some phenotypes may reflect developmental compensation or early-stage defects rather than the role of Lyl1 in adult hematopoiesis. To overcome these limitations, we generated a conditional knockout (cKO) mouse model that allows temporal and tissue-specific deletion of Lyl1. Here, we report the generation and validation of this novel cKO model and describe the consequences of Lyl1 deletion in adult hematopoiesis. Our findings provide new insight into the role of Lyl1 in maintaining lymphoid progenitor populations and uncover regulatory mechanisms essential for adult HSC-derived lymphopoiesis. Results Generation of a conditional Lyl1 KO model To investigate the role of Lyl1 in adult hematopoiesis, we generated a conditional Lyl1 KO mouse model using embryonic stem cells produced by the European Conditional Mouse Mutagenesis Program (EUCOMM)31. The targeting strategy inserted LoxP sites flanking exons 2 and 3 (Fig. 1A), which includes the start codon of the Lyl1 gene and encodes the bHLH domain essential for DNA binding21,32,33. Following FLP-mediated recombination, the resulting LoxP-flanked Lyl1 (Lyl1f/f) mouse line was crossed with Rosa26:creERT2 transgenic mice (hereafter referred to as E;) to enable tamoxifen (TAM)-inducible deletion. To induce Lyl1 loss in adulthood, E; Lyl1f/f mice were administered 2 doses of TAM at 6-8 weeks of age and analyzed 4 weeks later. The Lyl1 conditional knockout model.(A) Schematic of the Lyl1 conditional knockout construct (source EUCCOM)31. Exons of the Lyl1 locus are represented as grey boxes; primers for genotyping PCR (full arrows, top) and for quantitative RT–PCR (qRT-PCR; half arrows, bottom) are represented. (B) Genotyping PCR of bone marrow (BM) cells from individual E; Lyl1f/f mice with or without tamoxifen (TAM) treatment to confirm deletion of exons 2–3. The gel image shown is a cropped version for clarity; the full, uncropped gel with visible boundaries is provided in Fig. S1. (C) Expression of Lyl1 and Tal1 in total BM cells from E; Lyl1f/f mice, treated with TAM, assessed by qRT-PCR. Expression was normalized to Hprt and β-actin genes. Data are presented as mean ± SEM (n = 3 biological replicates), Student’s t-test: ***P<0.001 compared to untreated control mice; ns, not significant. We first confirmed deletion efficiency by PCR genotyping, which demonstrated successful excision of exons 2 and 3 (Fig. 1B and Fig. S1). Given the lack of commercially available antibodies that reliably detect endogenous murine Lyl1 protein by Western blotting, intracellular flow cytometry, or immunostaining, validation of gene inactivation was performed at the transcript level. Quantitative RT-PCR (qRT-PCR) confirmed efficient in vivo deletion with complete loss of Lyl1 transcript in bone marrow (BM) cells (Fig. 1C), without compensatory upregulation of the closely related TF gene Tal1. Collectively, these data support efficient genomic and transcript-level deletion of Lyl1, thereby providing a suitable Lyl1 cKO model for dissecting its role in adult hematopoiesis. Loss of Lyl1 disrupts HSPC homeostasis We next examined the consequences of Lyl1 deletion on hematopoietic output in adult mice. Loss of Lyl1 did not affect BM cellularity (Fig. S2A). Because Lyl1 is known to regulate MPPs in constitutive KO models12,13, we analyzed the Lineage-negative Sca-1+ and Kit+ (LSK) compartment (Fig. 2A), which is enriched for HSPCs that sustain hematopoietic homeostasis34. Total LSK numbers were comparable between TAM-treated E; Lyl1f/f mice and E; Lyl1+/+ controls (Fig. 2A). However, detailed subset analysis revealed selective reductions in HSPC subpopulations (Fig. 2B and Fig S2B). Of note, while analyses of relative frequencies reflect downstream differentiation output from LSK populations, absolute quantification, calculated by multiplying flow cytometric frequencies by total BM cellularity35–37, directly measures changes in the size of each progenitor pool. Using these complementary approaches, we observed a 2- to 4-fold reduction in HSCs, MPP with extensive megakaryocyte and erythroid potential (MPPMk/E), and MPPLy (Fig. 2B and Fig S2B), which supports downstream lymphopoiesis34,38. In contrast, MPPs with broad multilineage reconstitution potential (MPP) were preserved34. This pattern mirrors defects reported in constitutive Lyl1 KO models11,12, which similarly exhibit preferential loss of lymphoid-competent progenitors13,39. Hematopoietic phenotype of Lyl1 conditional deletion in adult mice.(A) Representative flow cytometric analysis (left) and absolute numbers (right) of Lineage-negative (Lin-) Sca-1+Kit+ (LSK) cells in the bone marrow (BM) of E; Lyl1+/+ and E; Lyl1f/f mice treated with vehicle (n = 3 for each genotype) or tamoxifen (TAM; n = 6 and 3), respectively. (B) Representative flow cytometric analysis (left) and proportion (right) of HSPC populations in the LSK compartment in the BM (n = 3 for all cohorts, except E; Lyl1+/+ treated with TAM n = 6). Hematopoietic stem cell (HSC) and multipotent progenitor (MPP) populations; megakaryocyte and erythroid biased (MPPMk/E), lymphoid-primed (MPPLy), and myeloid/granulocyte and monocyte biased (MPPG/M) MPP populations, as previously defined34. (C-D) Absolute number of B-, T- and myeloid cells in the BM (C) and thymocytes (D), assessed by flow cytometry. All analyses were performed 4 weeks after the last dose of TAM; Mean ± S.E.M. (n = 3 for all cohorts, except E; Lyl1+/+ treated with TAM n = 6), 2-way ANOVA with Tukey’s correction test; *P<0.05, **P<0.01 and ***P<0.001 compared to vehicle-treated controls. To determine whether these upstream perturbations impact downstream hematopoietic output, we quantified mature lineage populations in the BM (B, T, and myeloid) and thymus (T). Despite clear alterations at the progenitor level, absolute numbers of myeloid, B- and T-cell populations in the BM (Fig. 2C), as well as total thymocyte counts (Fig. 2D and Fig S2C), were not significantly affected by Lyl1 deletion. This contrasts with the pronounced defects in B-cell and DN2 T-cell progenitors observed in constitutive Lyl1 KO models12,13,26. Collectively, these findings indicate that while Lyl1 deletion in adult mice perturbs progenitor homeostasis, BM mature myeloid, B-, and T-cell numbers, as well as thymocyte numbers, are maintained at steady state, consistent with compensatory mechanisms. Conditional Lyl1 deletion impairs HSPC-derived lymphopoiesis in transplantation assays Steady-state analyses can mask functional deficits in HSCs, as normal lineage output may be maintained despite underlying impairments. In contrast, transplantation imposes a regenerative demand on HSCs, requiring them to fully reconstitute the hematopoietic system and thereby exposing functional deficiencies that are not apparent from phenotypic assessment alone40. To directly test whether Lyl1 loss impairs the functional capacity of adult HSPCs, we performed competitive BM transplantation assays (Fig. 3A). Importantly, TAM was administered only after successful engraftment was confirmed 4 weeks post-transplant, ensuring that observed effects reflect defects in HSPC maintenance and differentiation output rather than homing or initial engraftment efficiency. Donor chimerism was subsequently monitored in the peripheral blood (PB) over 20 weeks using our established protocol12,37,41. Lyl1-deleted cells exhibited a progressive and pronounced decline in PB reconstitution (Fig. 3B and S3A). This reduction was most evident within the T-cell compartment, whereas myeloid contribution increased over time (Fig. 3C and S3B), consistent with a lineage-biased functional impairment of HSPCs. Deletion of Lyl1 impairs adult HSPC-derived B- and T-lymphopoiesis. (A), Experimental schematic of competitive transplant using 1x106 BM cells from E; Lyl1+/+ and E; Lyl1f/f mice mixed in a 1:1 proportion with bone marrow (BM) cells harvested from isogenic Cd45.1+ (WT) mice. These cells were injected into lethally-irradiated recipients, and lineage reconstitution was monitored every 4 weeks, until 24 weeks post-transplantation when BM and thymus were harvested for analysis. Recipient mice were treated with 2 injections of either vehicle or tamoxifen (TAM; red arrows) after the first analysis was performed at 4-week post-transplantation and engraftment was confirmed. (B-C) Percent of donor-derived (Cd45.2+) E; Lyl1f/f white blood cells (WBC; B) and proportion of lineage-committed (Myeloid, B and T) cells (C) in the peripheral blood at the indicated time points post-transplant. Dashed line represents 50% engraftment. Mean ± S.E.M. (n = 6 per cohort), 2-way ANOVA with Tukey’s correction test; *P<0.05, **P<0.01 and ***P<0.001 compared to vehicle-treated controls. (D-E), Absolute numbers of Cd45.2+E; Lyl1f/f total BM cells (D; n = 12 per cohort) and Lineage-negative (Lin-) Sca-1+Kit+ (LSK) cells in the BM (E; n = 6 per cohort) of recipient mice at 24 weeks post-transplant. Mean ± S.E.M., Student’s t-test; **P<0.01 and ***P<0.001 compared to vehicle-treated controls. (F) Proportion of HSPC populations in the donor-derived E; Lyl1f/f LSK fraction in the BM of transplanted mice. Mean ± S.E.M. (n = 6 per cohort), 2-way ANOVA with Tukey’s correction test; *P<0.05 compared to vehicle-treated controls. Hematopoietic stem cell (HSC) and multipotent progenitor (MPP) populations; megakaryocyte and erythroid biased (MPPMk/E), lymphoid-primed (MPPLy), and myeloid/granulocyte and monocyte biased (MPPG/M) MPPs. (G) Absolute numbers of myeloid, B- and T-cells in the BM at 24 weeks post-transplant. Mean ± S.E.M. (n = 6 per cohort), 2-way ANOVA with Tukey’s correction test; **P<0.01 and ***P<0.001 compared to vehicle-treated controls. (H) Representative flow cytometric analysis (left) and absolute numbers (right) of donor-derived E; Lyl1f/f B-cell fractions in the BM of recipients at 24 weeks after transplantation. Mean ± S.E.M. (n = 6 per cohort), 2-way ANOVA with Tukey’s correction test; ***P<0.001 compared to vehicle-treated controls. Immunoglobulin (Ig)-negative (Ig-) B-cell progenitors; IgM-positive immature (IgM+) and IgD-positive mature (IgD+) fractions represented. (I) Proportion of donor-derived E; Lyl1f/f B-cell progenitor (Ig-) fractions in the BM of transplanted mice. Mean ± S.E.M. (n = 6 per cohort), 2-way ANOVA with Tukey’s correction test; **P<0.01 and ***P<0.001 compared to vehicle-treated controls. From early (pre-pro) to late (pre) fractions of B-cell progenitors represented. (J-K) Absolute numbers of donor-derived E; Lyl1f/f (J) thymocytes, and (K) T-cell populations, in the thymus of recipients at 24 weeks after transplantation. Representative flow cytometric analysis of T-cell populations featured in (K) CD4-CD8- double-negative (DN); CD4+CD8+ double-positive (DP), CD4+ or CD8+ single-positive (SP4 & SP8) populations. Mean ± S.E.M. (n=6 per cohort), 2-way ANOVA with Tukey’s correction test; *P<0.05 and **P<0.01 compared to vehicle-treated controls. (L) Representative flow cytometric analysis (left) and proportion (right) of each DN fraction within the intrathymic T-cell progenitor compartment. Mean ± S.E.M. (n=6 per cohort), 2-way ANOVA with Tukey’s correction test; **P<0.01 and ***P<0.001 compared to vehicle-treated controls. (M) Summary model of the role of Lyl1 in HSPC-derived hematopoiesis in adult mice. Megakaryocytes and erythroid cells (Mk/Erythroid). Colour intensity represents the relative output. To determine whether the impaired peripheral reconstitution following Lyl1 loss originates from defects in primitive hematopoietic compartments, we analyzed the BM of recipient mice at the experimental endpoint. This analysis revealed a 2-fold reduction in total BM cells derived from Lyl1-deficient donors (Fig. 3D), accompanied by a proportional decrease in LSK cells (Fig. 3E). Moreover, early HSPC subsets crucial for sustaining lymphopoiesis were significantly decreased, including HSCs (Fig. 3F) and MPPLy (Fig. S3C). Together, these findings indicate that Lyl1 is required for the maintenance and expansion of transplanted HSPCs under regenerative stress conditions. To determine whether the upstream defects in HSPCs translate into impaired lymphoid differentiation, we next examined downstream hematopoietic lineages. Loss of Lyl1 resulted in an approximately 4-fold reduction of donor-derived B and T cells in the BM (Fig. 3G and S3D). Within the B-cell lineage, both mature (IgD+) and immature (IgM+) populations were significantly decreased, along with a reduction in B-cell progenitors (Ig-; Fig. 3H). Further resolution of the progenitor compartment revealed a differentiation block at the pro-B cell stage (Fig. 3I and S3E), consistent with prior reports in constitutive KO models13. In the thymus, donor-derived thymocytes were decreased by approximately 10-fold (Fig. 3J), with a marked reduction across all T-cell differentiation subsets, including DN progenitors, CD4+ CD8+ double-positive (DP) cells, and single-positive CD4+ helper (SP4) and CD8+ cytotoxic (SP8) populations (Fig. 3K). Detailed analysis of the DN compartment further revealed an early developmental arrest at the DN1 stage (Fig. 3L and S3F). Together, these findings demonstrate that Lyl1 is essential for sustaining HSPC-derived T- and B- cell lymphopoiesis in adult mice (Fig. 3M). Discussion In this study, we generated a conditional KO mouse model to define the role of Lyl1 in adult hematopoiesis. Conditional deletion of Lyl1 resulted in reduced frequencies and absolute numbers of HSCs and MPPLy at steady state (Fig. 2B and S2B), consistent with findings from constitutive Lyl1 KO models11,12. Despite these upstream perturbations, mature myeloid and lymphoid cell numbers remained unchanged under homeostatic conditions (Fig. 2C-D), in contrast to reports from embryonically-deleted Lyl1 mouse models12,13. The preservation of mature lineage output despite reduced MPPLy pools likely reflects the intrinsic compensatory capacity of the hematopoietic system. Multipotent progenitors can dynamically adjust their proliferation and differentiation to maintain output, and lymphoid lineages in adulthood arise from multiple progenitor sources, underscoring the functional plasticity of the MPP compartment38,42–47. Together, these mechanisms buffer the impact of reduced MPPLy numbers at steady state, whereas regenerative stress conditions, such as competitive transplantation, reveal non-redundant requirement for Lyl1 in sustaining lymphopoiesis. Collectively, these findings indicate that Lyl1 is dispensable for steady-state hematopoietic maintenance in adult mice but becomes critical under conditions that challenge HSPC function, highlighting a more prominent role during developmental and stress hematopoiesis. Consistent with this model, competitive transplantation assays revealed that conditional ablation of Lyl1 resulted in marked defects in HSPC maintenance (Fig. 3B and F) and a progressive loss of B- and T-cell output (Fig. 3C and G). These findings align with emerging evidence that lymphocytes of embryonic origin can persist into adulthood47, with multipotent progenitors, rather than HSCs alone, contributing substantially to lymphoid lineages10,48–50. Together, our data suggest that Lyl1-dependent lymphopoiesis in adult mice reflects contributions from both embryonic and adult-derived progenitor waves, with Lyl1 acting at multiple hierarchical levels to sustain lymphoid output under regenerative demand. Unlike other members of the TF heptad (Fli1, Erg, Gata2, Runx1, Lmo2, and Tal1) or their transcriptional cofactor Ldb1, which are essential for hematopoietic development8,51–60, Lyl1 is largely dispensable for embryonic hematopoiesis13. In adult HSCs, both Lyl1 and its paralog Tal1 are individually dispensable for HSC maintenance61, with Tal1-deleted HSCs persisting through functional redundancy with Lyl112. These closely-related TFs nonetheless appear to regulate distinct hematopoietic compartments, with conditional deletion of Tal1 preferentially affecting MPPs62, whereas Lyl1 deletion predominantly impacts HSCs and lymphoid-primed progenitor pools (Fig. 2B and 3F). Functionally, loss of either Lyl1 or Tal1 impairs HSC fitness and reduces multilineage repopulation potential11–13,62. Their redundancy also extends to definitive erythropoiesis and megakaryopoiesis29,30, while their roles in myeloid and lymphoid specification diverge more clearly: Tal1 is critical for myelopoiesis62, while Lyl1 is indispensable for lymphoid development, as evidenced by impaired B- and T-cell generation from Lyl1-deleted HSPCs (Fig. 3G-L). Although constitutive Lyl1 KO models established its role in lymphoid development11–13,26, germline deletion of Lyl1 precluded dissection of the relative contributions of embryonic versus adult HSCs to this phenotype. Given increasing evidence that adult lymphopoiesis derives from both HSC- and embryonically imprinted progenitor-derived waves47,63–65, our conditional model provides a unique framework to resolve stage-specific requirements for Lyl1 across developmental hierarchies. Future studies leveraging this system could integrate RNA-seq and ATAC-seq of Lyl1-deficient versus control HSCs to define the transcriptional and chromatin landscapes governed by Lyl1, thereby elucidating its direct molecular targets and regulatory circuits. In addition, comparative transplantation approaches using purified fetal and adult HSCs followed by inducible Lyl1 deletion after engraftment would enable to dissect assessment of developmental context-dependent requirements for Lyl1 in hematopoietic output. Beyond hematopoiesis, Lyl1 is expressed in multiple tissues and has been implicated in diverse developmental processes outside the blood system28,66–69. Accordingly, this conditional model also provides a platform for investigating Lyl1 function in non-hematopoietic contexts. Together, these studies establish a foundation for dissecting the stage-specific and lineage-specific roles of Lyl1 in vivo and for defining the molecular mechanisms by which it regulates hematopoietic and broader developmental programs. Methods Ethics declaration All experiments were pre-approved by the Alfred Research Alliance (ARA) Animal Ethics Committee, and all procedures were performed with the relevant guidelines and regulations. Mice were euthanized by trained personnel using carbon dioxide (CO₂) inhalation at a slow fill rate (20% chamber volume per minute), following institutional Animal Facility procedures. Once respiration and movement ceased, the absence of vital signs was confirmed by palpation, followed by bilateral thoracotomy to ensure death. All procedures regarding the study design, animal experiments, statistical analysis, and data reporting fulfil the criteria of the ARRIVE guidelines (https://arriveguidelines.org)66. Mouse experiments using genetic models The new Lyl1 conditional knockout mouse (Lyl1f/f) model was generated by Australian Phenomics Network from embryonic stem (ES) cells containing the conditional Lyl1 construct designed and produced by European Conditional Mouse Mutagenesis Programme (EUCOMM). The construct contained LoxP sites flanking exons 2 and 3 of the Lyl1 gene including the start codon, as well as a LacZ/Neo sequence, between exons 1 and 2 that was flanked by FRT sites, which was removed by crossing the Lyl1f/f mouse line with flippase-expressing (FLP) mice (Monash University). Homozygous Lyl1f/f mice were crossed with Rosa26:creERT2 transgenic (creERT2Tg herein E). All mouse lines were backcrossed onto a C57BL/6J background for 10 generations and maintained in pathogen-free conditions according to institutional animal care guidelines. Routine genotyping of the Lyl1 targeted (Lyl1f/f) locus was carried out by PCR using the primers Lyl1_P1-Fw (CTTAGAGCCCAGCAAACG), Lyl1_P2-Rv (CAATGTAAGAGCACCCTTAGG) and Lyl1_P4-Rv (ATCAACCACTTTGTACAAGAAA). At the same time, Cre-induced Lyl1 deletion (Lyl1) was assessed by PCR using the primers Lyl1_P1-Fw and Lyl1_P6-Rv (GCTCAGACCATAACTTCG). Tamoxifen preparation 90mg of tamoxifen ( H7904, Sigma) was diluted in 150ul of 100% EtOH, with peanut oil ( P2144, Sigma) added up to 1.5 mL, and this solution was incubated at 50°C with frequent vortexing until complete dissolution. For in vivo studies, tamoxifen solution was administered (2.8L/g) on 2 consecutive days by oral gavage (168mg/kg, final dose), using a curved 22G, 3.8cm length stainless steel needle. Quantitative RT-PCR Bone marrow cells were harvested and resuspended in Trizol reagent (Invitrogen). cDNA was prepared using First strand Transcriptor cDNA kit (Roche). Primers were designed using the Roche Universal Probe Library (UPL) – Assay Design Center along with the corresponding fluorescent UPL probed. RT-PCR was performed on Roche Lightcycler 480 II (Roche Diagnostics Australia, Castle Hill, NSW). Exon 2-3 (Lyl1_ex2_Fw ATTACCACCCTCACCCCTTC and Ly1_ex3_Rv CCGGCTGTTAGGGAAGATG) and exon 3-4 (Lyl1_ex3_Fw GCAGGACCCTTCAGCATCT and Lyl1_ex4_Rv CCACCTTCTGGGGTTGGT) were used for assessing Lyl1 expression. Delta delta Ct values were calculated by using Ct values from Hprt and β-actin genes as reference. Flow cytometry analyses Flow cytometry analysis and cell sorting were done as previously described67,68 on single cell suspensions stained using BD Pharmingen antibodies (BD Australia, North Ryde NSW, Australia) against mouse CD4 (RM4-5), CD8a (53-6.7), CD25 (PC61.5), CD44 (IM7), CD45.1 (A20), CD45.2 (104), Thy1.2 (53-2.1; #561616), TCRβ (H57-597), CD117 (ACK45), CD135 (A2F10.1), CD150 (TC15-12F12.2; #562373), B220 (RA3-6B2; #563708), CD3 (145-2C11; #563004), CD19 (ID3; #557655), Gr-1 (RB6-8C5; #563299 and #565033), CD11b (M1/70; #563015 and #560455), Ter119 (Ter119; #565523 and #557909), and Sca-1 (D7; #558160). DN3 populations were stained using BioLegend monoclonal antibody (Australian Biosearch, Balcatta WA, Australia) against mouse CD28 (E18). Apoptosis was measured using an antibody against AnnexinV (#556420, BD Australia) and the permeable Sytox Blue (BD Australia) following the manufacturer’s protocol. FACS analysis was performed using LSRII and LSR Fortessa cytometers. Cell sorting was performed with a FACSAria or BD Influx. Isogenic murine transplantation assays Competitive transplantation assays were performed by intravenously injecting equal numbers (1x106) of donor Cd45.2+ and competitor Cd45.1+ BM cells into lethally-irradiated (2 doses of 5.5 Gy, 4 hours apart) isogenic Ly5.1 (Cd45.1) recipient mice37,69. Hematopoietic reconstitution was monitored by flow cytometric analysis of peripheral blood collected from recipients at the indicated time points. Statistical analyses were performed using GraphPad Prism 8.0 software (GraphPad Software Inc, San Diego, CA). Supplementary Information Supplementary Information. Acknowledgements We thank Geza Paukovics, Eva Orlowski-Oliver and Magdaline Costa from the Alfred Research Alliance (ARA) FlowCore for assistance with flow cytometry. We also thank Veronique Litalien and Loretta Cerruti for technical assistance. Author contributions S.K.C. performed the experiments, analyzed data and wrote the manuscript; J.T. J.S., and J.A.B. performed research and analyzed data; D.J.C. designed the study, analyzed the data and wrote the manuscript; C.S.T. designed, supervised, and performed research, coordinated the interactions between the authors, interpreted the results and wrote the manuscript; and all authors critically reviewed the manuscript. Funding This study was supported by laboratory start-up funds from the CancerCare Manitoba Foundation and the University of Manitoba (C.S.T.), research funding from the National Health and Medical Research Council (NHMRC) Project Grant APP1165840 (D.J.C. and C.S.T.) and Senior Medical Research Fellowship APP1139466 (D.J.C.). Data availability All relevant data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. David J. Curtis and Cedric S. Tremblay These authors contributed equally to this work. References Associated Data Supplementary Materials Supplementary Information. Data Availability Statement All relevant data that support the findings of this study are available from the corresponding author upon reasonable request.